Who Paid My Doc
Rajen Mody
Pediatric Hematology-Oncology Ann Arbor, MI Medical Doctor
NPI 1548270176 CMS profile 251084
1500 E Medical Center Dr, Ann Arbor, MI 48109
General payments
$23,723
Research payments
$140
Ownership & investment interest
$0
Research they led as principal investigator
$2,469,496
Through program year 2025, Rajen Mody of Ann Arbor, MI is reported in the CMS Open Payments database as having received $23,723 across 43 general payments and $140 in research payments paid to them. Separately, studies naming them as principal investigator received $2,469,496 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 85th percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $650 | 3 | |
| 2024 | General | $1,131 | 5 | |
| 2023 | General | $9,562 | 8 | |
| 2022 | General | $963 | 3 | |
| 2021 | General | $1,429 | 3 | |
| 2021 | Research | $140 | 1 | |
| 2020 | General | $1,925 | 3 | |
| 2019 | General | $8,064 | 18 |
Beside peers
- Rajen Mody
- Pediatric Hematology-Oncology median
- Middle half of Pediatric Hematology-Oncology
- National median
In program year 2025, general payments to Rajen Mody were reported at $650. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.
Show as a table
| Year | Rajen Mody | Pediatric Hematology-Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $8,064 | $184 | $69–$2,094 | $163 |
| 2020 | $1,925 | $220 | $37–$3,941 | $114 |
| 2021 | $1,429 | $366 | $63–$4,909 | $132 |
| 2022 | $963 | $181 | $66–$2,775 | $149 |
| 2023 | $9,562 | $175 | $62–$2,600 | $160 |
| 2024 | $1,131 | $227 | $66–$2,992 | $164 |
| 2025 | $650 | $204 | $80–$2,819 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
44 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Hematology-Oncology in Michigan
Steven Pipe
Pediatric Hematology-Oncology · Ann Arbor, MI
Angela Weyand
Pediatric Hematology-Oncology · Ann Arbor, MI
Michael Callaghan
Pediatric Hematology-Oncology · Detroit, MI
Jordan Shavit
Pediatric Hematology-Oncology · Ann Arbor, MI
Roshni Kulkarni
Pediatric Hematology-Oncology · Lansing, MI
Ahmar Zaidi
Pediatric Hematology-Oncology · Detroit, MI
Related records
Pediatric Hematology-Oncology in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Hematology-Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.